Comparative Efficacy of Ertugliflozin (ERTU) plus Sitagliptin (SITA) vs. Other Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) + Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Combinations: Model-Based Meta-analysis (MBMA) of HbA1c Lowering

被引：0

作者：

Fediuk, Daryl

Mandema, Jaap

Sweeney, Kevin

Terra, Steven G.

Sahasrabudhe, Vaishali

机构：

来源：

DIABETES | 2019年 / 68卷

关键词：

D O I：

10.2337/db19-2362-PUB

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2362-PUB

引用

页数：2

共 23 条

[1] Comparative Efficacy of Ertugliflozin (ERTU) vs. Other Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i): Model-Based Meta-analysis (MBMA) of HbA1c Lowering
Fediuk, Daryl
Mandema, Jaap
Sweeney, Kevin
Terra, Steven G.
Sahasrabudhe, Vaishali
DIABETES, 2019, 68
[2] Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) vs. Dipeptidyl Peptidase 4 Inhibitor (DPP4i) as Initiator Therapy with Type 2 Diabetes on Cardiovascular Outcomes -A Systematic Review and Meta-analysis
Shrestha, Abhigan B.
Rajak, Kripa
Tummala, Nayanika
Maddineni, Gautam
DIABETES, 2024, 73
[3] Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) versus dipeptidyl peptidase 4 inhibitors (DPP-4i) in T2D patients across different HBA1c levels
D'Andrea, Elvira
Wexler, Deborah
Paik, Julie
Alt, Ethan
Kim, Seoyoung
Patorno, Elisabetta
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 331 - 332
[4] Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
Se Hee Min
Jeong-Hwa Yoon
Sun Joon Moon
Seokyung Hahn
Young Min Cho
Scientific Reports, 8
[5] Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
Min, Se Hee
Yoon, Jeong-Hwa
Moon, Sun Joon
Hahn, Seokyung
Cho, Young Min
SCIENTIFIC REPORTS, 2018, 8
[6] Factors related to sodium glucose cotransporter 2 inhibitor (SGLT2i) and dipeptidyl peptidase 4 inhibitor (DPP4i) dispensing among naive, incident, and prevalent new users
Qiang, Yandong
Horgan, Casie H.
Petrone, Andrew B.
Kolonoski, Joy
Hansbury, Aaron
Hampp, Christian
Dutcher, Sarah
Adimadhyam, Sruthi
Toh, Sengwee
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 64 - 65
[7] INDIRECT COMPARISON TO EVALUATE THE EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS (DPP4I) AND SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS (SGLT2I) ADDED TO INSULIN THERAPY IN TYPE 2 DIABETES
Yoon, J.
Min, S. H.
Hahn, S.
Cho, Y. M.
VALUE IN HEALTH, 2015, 18 (07) : A599 - A599
[8] Model-Based Meta-Analysis of the HbA1c Lowering Effect of PF-04971729, a Sodium Glucose Co-Transporter-2 Inhibitor (SGLT2i), in Comparison With Other SGLT2i and Anti-Diabetic Agents (ADA)
Mandema, Jaap
Sweeney, Kevin
Terra, Steven
Sahasrabudhe, Vaishali
DIABETES, 2012, 61 : A260 - A260
[9] MODEL-BASED META-ANALYSIS (MBMA) OF THE HbA1c LOWERING EFFECT OF SGLT-2 INHIBITORS (SGLT2i): IMPACT OF BASELINE HbA1c, RENAL FUNCTION AND BACKGROUND TREATMENT.
Mandema, J.
Terra, S.
Sweeney, K.
Sahasrabudhe, V.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S33 - S33
[10] Can Baseline Hemoglobin A1c Help Guide Treatment with an SGLT2i vs. DPP-4i? A Meta-analysis
Page, Stephanie O.
Mishriky, Basem M.
Uhrig, Jarrod
Sewell, Kerry
Mian, Muna R.
Powell, James R.
Cummings, Doyle M.
DIABETES, 2019, 68

← 1 2 3 →